Skip to content

Clinical efficacy of taVNS combined with conventional swallowing rehabilitation for subacute post-stroke dysphagia: a randomized, controlled, double-blind trial

Clinical efficacy of taVNS combined with conventional swallowing rehabilitation for subacute post-stroke dysphagia: a randomized, controlled, double-blind trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125460
Enrollment
Unknown
Registered
2026-05-27
Start date
2026-05-30
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

True Stimulation Group:True taVNS stimulation combined with guideline-based conventional dysphagia rehabilitation, with the intensity set at the maximum tolerable level for the subjects.
Sham Stimulation Group:Sham taVNS stimulation combined with conventional dysphagia rehabilitation based on guidelines, the stimulation intensity for the first 30 seconds is the maximum tolerable value

Sponsors

The Eighth Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with stroke based on cranial CT or MRI imaging; 2. Stroke in the subacute phase, with a course of >7 days and <=6 months; 3. Aged 30-80 years; 4. Diagnosed with swallowing dysfunction via VFSS or FEES, with an FOIS score <7; 5. Conscious and able to cooperate with study-related assessments or procedures; 6. Voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Presence of skin damage or skin lesions at the stimulation site of the left ear (such as sunburn, cuts, open abscesses, dermatitis, ulcers, etc.); 2. Obvious sensory impairment in the ear; 3. Presence of other diseases that may affect swallowing function, such as head and neck cancer, Parkinson's disease, Alzheimer's disease, etc.; 4. Active epilepsy or having had a seizure within the past 6 months, or other severe neurological diseases judged as unsuitable for neuroregulation intervention; 5. Presence of implanted electrical stimulation or neuroregulation devices in the body (such as invasive vagus nerve stimulation, deep brain stimulation, spinal cord stimulators), cardiac pacemaker/implantable cardioverter defibrillator, or other electronic implants that may cause electrical interference (such as cochlear implants); 6. Severe cardiac or other organ dysfunction, or other life-threatening systemic diseases, or currently in a clinically unstable period (for example, recent severe infection, respiratory failure requiring mechanical ventilation, circulatory instability, etc.); 7. Progressive stage of stroke; 8. Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
Functional Oral Intake Scale, FOIS;

Secondary

MeasureTime frame
Rosenbek penetration-aspiration scale, PAS;dysphagia outcome and severity scale, DOSS;modified Mann assessment of swallowing ability, mMASA;

Countries

China

Contacts

Public ContactShaofeng Zhao

The Eighth Affiliated Hospital of Sun Yat-sen University

zhaosf1@163.com+86 188 9877 3680

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026